This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation. Patient demographics will be collected at baseline for all patients. A baseline FIX activity and Bethesda assay for inhibitor based on historical data should be recorded if available. Adverse events as defined in the protocol will also be reported on the appropriate forms. Data will be collected from patients on an ongoing basis to ensure that information is being captured for each patient being treated with BeneFIX.
Study Type
OBSERVATIONAL
Enrollment
218
Unnamed facility
Vienna, Austria
Unnamed facility
Brussels, Belgium
Unnamed facility
Brussels, Belgium
Unnamed facility
Brussels, Belgium
Unnamed facility
Edegem, Belgium
Unnamed facility
Leuven, Belgium
Unnamed facility
Montegnée, Belgium
Unnamed facility
Amiens, France
Unnamed facility
Angers, France
Unnamed facility
Caen, France
...and 80 more locations
Observation for safety
Time frame: Study Duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.